Literature DB >> 26718964

Complex analysis of the p53 tumor suppressor in lung carcinoma.

Jana Smardova1, Kvetoslava Liskova1, Barbora Ravcukova2, Jitka Malcikova3, Jitka Hausnerova1, Miluse Svitakova1, Renata Hrabalkova1, Lenka Zlamalikova1, Katerina Stano-Kozubik3, Ivona Blahakova3, Jana Speldova4, Jiri Jarkovsky5, Jan Smarda6.   

Abstract

Lung cancer is the leading cause of cancer-related deaths worldwide. The p53 tumor suppressor is a transcription factor controlling expression of its target genes in response to various stress stimuli. Mutations of the TP53 gene occur very frequently in lung carcinomas and they play an important role in both oncogenic transformation of lung epithelial cells and lung carcinoma progression. We determined the TP53 status in 42 samples of squamous cell lung carcinoma (SQCC) and 56 samples of lung adenocarcinoma (AC) by the functional analysis FASAY and its variant called split assay. Altogether, we detected 64 TP53 mutations in 63 patients and analyzed them by cDNA and gDNA sequencing. The TP53 mutations were found in 76.2% (32/42) of SQCC cases, and 55.4% (31/56) of ACs. Immunoblotting revealed the p53 protein accumulation in 18 samples (42.9%) among SQCC cases and 19 samples (33.9%) among AC cases. Using fluorescence in situ hybridization we detected loss of the TP53-specific 17p13.3 locus in 23 from 41 analyzed SQCC samples (56.1%) and in 20 from 54 analyzed AC samples (37.0%). We did not find any statistically significant differences in overall and disease-free survival in relation to TP53 status.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26718964     DOI: 10.3892/or.2015.4533

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  7 in total

1.  Knockdown of GluA2 induces apoptosis in non-small-cell lung cancer A549 cells through the p53 signaling pathway.

Authors:  Hong-Yan Zhang; Wei Yang; Ji-Bin Lu
Journal:  Oncol Lett       Date:  2017-05-24       Impact factor: 2.967

Review 2.  USP28: Oncogene or Tumor Suppressor? A Unifying Paradigm for Squamous Cell Carcinoma.

Authors:  Cristian Prieto-Garcia; Ines Tomašković; Varun Jayeshkumar Shah; Ivan Dikic; Markus Diefenbacher
Journal:  Cells       Date:  2021-10-04       Impact factor: 6.600

Review 3.  When tumor doesn't read textbook. Third case of TTF1 and p40 co-expression in the same tumour cells in a non-small cell carcinoma. A potential new entity to consider?

Authors:  M Spinelli; J Khorshad; P Viola
Journal:  Pathologica       Date:  2019-06

4.  Clinical roles of the aberrantly expressed lncRNAs in lung squamous cell carcinoma: a study based on RNA-sequencing and microarray data mining.

Authors:  Wen-Jie Chen; Rui-Xue Tang; Rong-Quan He; Dong-Yao Li; Liang Liang; Jiang-Hui Zeng; Xiao-Hua Hu; Jie Ma; Shi-Kang Li; Gang Chen
Journal:  Oncotarget       Date:  2017-05-22

5.  Clonal Evolution of TP53 c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC).

Authors:  Marica Garziera; Erika Cecchin; Giorgio Giorda; Roberto Sorio; Simona Scalone; Elena De Mattia; Rossana Roncato; Sara Gagno; Elena Poletto; Loredana Romanato; Fabrizio Ecca; Vincenzo Canzonieri; Giuseppe Toffoli
Journal:  Cells       Date:  2019-10-01       Impact factor: 6.600

6.  Clinical, Genetic, and Prognostic Features of Adrenocortical Tumors in Children: A 10-Year Single-Center Experience.

Authors:  Evelina Miele; Angela Di Giannatale; Alessandro Crocoli; Raffaele Cozza; Annalisa Serra; Aurora Castellano; Antonella Cacchione; Maria Giuseppina Cefalo; Rita Alaggio; Maria Debora De Pasquale
Journal:  Front Oncol       Date:  2020-10-15       Impact factor: 6.244

7.  Somatic intronic TP53 c.375+5G mutations are a recurrent but under-recognized mode of TP53 inactivation.

Authors:  M Herman Chui; Ciyu Yang; Nikita Mehta; Vikas Rai; Ahmet Zehir; Amir Momeni Boroujeni; Marc Ladanyi; Diana Mandelker
Journal:  J Pathol Clin Res       Date:  2021-09-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.